TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > TGA Advertisement Framework Revisions Hard at Work During Pandemic Times

TGA Advertisement Framework Revisions Hard at Work During Pandemic Times

Inspection

Author: Luis Jimenez

Marking the second year after the issuance of the revised TGA Advertising framework, the TGA has evidenced a strong hard-line position on enforcements against the illegal import, supply, and advertising of therapeutic goods into Australia during the fiscal year for 2019-2020 (starting in July).

During the twelve months, 187 infringement notices were issued totalling almost $1.8 million in fines. The TGA also pursued civil court cases against three companies.

In direct response to COVID-19 advertising, there were 58 infringement notices (representing 31% of all notices for the fiscal year) totalling $549 thousand in fines. The COVID-19 related false advertisement trend has continued in August and TGA will likely continue to carefully monitor any advertisements involving COVID-19 to ensure the safety of the public. In some instances, this could even include social media, as was seen in a widely publicised case in which an Australian media character with 1.4 million subscribers was issued a hefty fine as a result of a Facebook live stream where unsupported COVID-19 related claims were made.

As with most regulators the array of actions that the TGA can take include several avenues depending on the magnitude of the violation:

  • Warning letters
  • Suspensions
  • Cancellations
  • Recall actions
  • Advertising directions notices
  • Infringement notices
  • Enforceable undertakings
  • Injunctions
  • Civil penalties
  • Criminal prosecutions
  • Advertising complaints outcomes
  • Listed medicine compliance review outcomes

The TGA calculates the amount payable for an infringement notice using the formula in the Act (subsection 42YKA(3)). Below is a representation of the formula:

In respect to the total amounts, the TGA state:

“We do not have discretion to set the value of the infringement notice even if we are of the view the particular alleged offence may warrant a higher amount.”

For a description of details on what each action entails and lists of recent enforcement actions on each click here.

An independent assessment of the new Advertisement Framework:

On June 2020, the TGA published the independent report announced in 2018 by Australia’s Minister of Health to examine the impact of the Therapeutic Goods advertisement framework. Amongst other items including educational programs of the industry, the revised framework includes:

  • Increased clarity and objectivity to support the compliance and enforcement powers in the Act and improved consistency between the requirements for medicines and medical devices;
  • Appointed the TGA as the single body responsible for implementing a complaints management process about the advertising of therapeutic goods to the public; and
  • Broadened sanctions and penalties to deter inappropriate and misleading advertising of therapeutic goods.

The assessment evaluated activities over the 12-18 month period after the implementation of the changes to the advertisement framework, namely 2018 to February 2020. The final report on the impact of advertising reforms from the Expert Panel Review outlined a total of 22 recommendations, which were all supported by the Government. Here is an overall overview of the TGA’s key takeaways and plans.

“The agreed actions, once implemented, will deliver improvements and refinements to the therapeutic goods advertising framework, including:

  • the development, in consultation with stakeholders, of annual advertising compliance priorities, for outcomes and consumer-focused approach to advertising compliance;
  • implementation of more strategic advertising complaints handling that uses complaints as a source of intelligence, to be used for individual case selection and in determining compliance priorities;
  • the development and publication of new key performance indicators focused on priorities and outcomes rather than processes and deadlines;
  • the publication of case studies based on case experience to assist advertisers and consumers to understand the legal requirements for advertising therapeutic goods, in conjunction with the ongoing publication of policy clarification as needed;
  • improved flexibility, so as to be adaptable to emerging issues, and improved transparency through media and publications, as modelled on our response to compliance during the COVID-19 pandemic;
  • implementation of an education and stakeholder engagement strategy, aligned with compliance priorities and supported by education priorities, which focuses on consumer and industry benefit;
  • enhanced collaboration and engagement with other Australian regulators; and
  • enhancing the operation of the Therapeutic Goods Advertising Consultative Committee.”

Use of the Advertisement Framework in response to COVID-1

“Since the analysis included the initial months of the COVID-19 environment, it provided an opportunity for the TGA to demonstrate the value to consumers of focusing on compliance priorities, taking a strategic approach to communication and education tasks, and adopting an agile approach to the use of its enhanced powers.”

The report refrained from making specific recommendations about the COVID-19 related response, but provide some insight into the mindset of the TGA indicating.

“In consultations conducted towards the end of the review, Departmental staff indicated that there had been an internal shift in attitude, towards much more hardline enforcement in response to the more serious risk atmosphere presented by misleading advertising around COVID-19 claims. In recent times, there has also been increased media coverage of inappropriate and misleading COVID-19 related therapeutic goods advertising, and the fines that have been handed out. This has been supported by increased use of multiple public notices, particularly to warn consumers about illegal advertising about COVID-19. The Departmental staff comments, a high-level overview of information from the compliance database, and the media coverage of recent cases indicate that there has been an increase in the timely use of stronger enforcement responses, such as fines and public notices, with regard to COVID-related advertising.

The COVID-19 experience also has useful learnings regarding the use of media and publicising the compliance actions taken by the TGA to raise awareness of the negative consequences of using non-compliant advertising.”

Conclusion

TGA seem to strike a good balance on active, intelligent, and alert monitoring of breaches to the advertisement code. Seemingly, the main areas of concern of social media and use of the media to advertise are being effectively employed by the TGA to educate and motivate the industry to stay compliant. The use of media to publicise fines and attract media attention to those that breach the code, maybe in many cases, more harm than the actual fines.

The new advertisement framework provides requirements for any advertisement and marketing activity in Australia. Please reach out to us if you have questions regarding the compliance of your advertisement activities in Australia.

References:

Main article source published by TGA on July 8th 2020: https://www.tga.gov.au/media-release/tga-issues-fines-nearly-18-million-alleged-illegal-activity-2019-20

Report for Review of Therapeutic Goods Advertising Framework-August 10th 2020:
https://www.tga.gov.au/sites/default/files/review-therapeutic-goods-advertising-framework.pdf

Australian Government response to the Review of the Reforms to the Therapeutic Goods Advertising Framework-August 10th 2020: https://www.tga.gov.au/australian-government-response-review-reforms-therapeutic-goods-advertising-framework

TGA issues fines of nearly $1.8 million for alleged illegal activity in 2019-20:
https://www.tga.gov.au/media-release/tga-issues-fines-nearly-18-million-alleged-illegal-activity-2019-20

We tailor our services to the requirements of your business and can help you implement plans that are best suited to your projects. 

Marking the second year after the issuance of the revised TGA Advertising framework, the TGA has evidenced a strong hard-line position on enforcements against the illegal import, supply, and advertising of therapeutic goods into Australia during the fiscal year for 2019-2020 (starting in July).

During the twelve months, 187 infringement notices were issued totalling almost $1.8 million in fines. The TGA also pursued civil court cases against three companies.

In direct response to COVID-19 advertising, there were 58 infringement notices (representing 31% of all notices for the fiscal year) totalling $549 thousand in fines. The COVID-19 related false advertisement trend has continued in August and TGA will likely continue to carefully monitor any advertisements involving COVID-19 to ensure the safety of the public. In some instances, this could even include social media, as was seen in a widely publicised case in which an Australian media character with 1.4 million subscribers was issued a hefty fine as a result of a Facebook live stream where unsupported COVID-19 related claims were made.

As with most regulators the array of actions that the TGA can take include several avenues depending on the magnitude of the violation:

  • Warning letters
  • Suspensions
  • Cancellations
  • Recall actions
  • Advertising directions notices
  • Infringement notices
  • Enforceable undertakings
  • Injunctions
  • Civil penalties
  • Criminal prosecutions
  • Advertising complaints outcomes
  • Listed medicine compliance review outcomes

The TGA calculates the amount payable for an infringement notice using the formula in the Act (subsection 42YKA(3)). Below is a representation of the formula:

In respect to the total amounts, the TGA state:

“We do not have discretion to set the value of the infringement notice even if we are of the view the particular alleged offence may warrant a higher amount.”

For a description of details on what each action entails and lists of recent enforcement actions on each click here.

An independent assessment of the new Advertisement Framework:

On June 2020, the TGA published the independent report announced in 2018 by Australia’s Minister of Health to examine the impact of the Therapeutic Goods advertisement framework. Amongst other items including educational programs of the industry, the revised framework includes:

  • Increased clarity and objectivity to support the compliance and enforcement powers in the Act and improved consistency between the requirements for medicines and medical devices;
  • Appointed the TGA as the single body responsible for implementing a complaints management process about the advertising of therapeutic goods to the public; and
  • Broadened sanctions and penalties to deter inappropriate and misleading advertising of therapeutic goods.

The assessment evaluated activities over the 12-18 month period after the implementation of the changes to the advertisement framework, namely 2018 to February 2020. The final report on the impact of advertising reforms from the Expert Panel Review outlined a total of 22 recommendations, which were all supported by the Government. Here is an overall overview of the TGA’s key takeaways and plans.

“The agreed actions, once implemented, will deliver improvements and refinements to the therapeutic goods advertising framework, including:

  • the development, in consultation with stakeholders, of annual advertising compliance priorities, for outcomes and consumer-focused approach to advertising compliance;
  • implementation of more strategic advertising complaints handling that uses complaints as a source of intelligence, to be used for individual case selection and in determining compliance priorities;
  • the development and publication of new key performance indicators focused on priorities and outcomes rather than processes and deadlines;
  • the publication of case studies based on case experience to assist advertisers and consumers to understand the legal requirements for advertising therapeutic goods, in conjunction with the ongoing publication of policy clarification as needed;
  • improved flexibility, so as to be adaptable to emerging issues, and improved transparency through media and publications, as modelled on our response to compliance during the COVID-19 pandemic;
  • implementation of an education and stakeholder engagement strategy, aligned with compliance priorities and supported by education priorities, which focuses on consumer and industry benefit;
  • enhanced collaboration and engagement with other Australian regulators; and
  • enhancing the operation of the Therapeutic Goods Advertising Consultative Committee.”

Use of the Advertisement Framework in response to COVID-1

“Since the analysis included the initial months of the COVID-19 environment, it provided an opportunity for the TGA to demonstrate the value to consumers of focusing on compliance priorities, taking a strategic approach to communication and education tasks, and adopting an agile approach to the use of its enhanced powers.”

The report refrained from making specific recommendations about the COVID-19 related response, but provide some insight into the mindset of the TGA indicating.

“In consultations conducted towards the end of the review, Departmental staff indicated that there had been an internal shift in attitude, towards much more hardline enforcement in response to the more serious risk atmosphere presented by misleading advertising around COVID-19 claims. In recent times, there has also been increased media coverage of inappropriate and misleading COVID-19 related therapeutic goods advertising, and the fines that have been handed out. This has been supported by increased use of multiple public notices, particularly to warn consumers about illegal advertising about COVID-19. The Departmental staff comments, a high-level overview of information from the compliance database, and the media coverage of recent cases indicate that there has been an increase in the timely use of stronger enforcement responses, such as fines and public notices, with regard to COVID-related advertising.

The COVID-19 experience also has useful learnings regarding the use of media and publicising the compliance actions taken by the TGA to raise awareness of the negative consequences of using non-compliant advertising.”

Conclusion

TGA seem to strike a good balance on active, intelligent, and alert monitoring of breaches to the advertisement code. Seemingly, the main areas of concern of social media and use of the media to advertise are being effectively employed by the TGA to educate and motivate the industry to stay compliant. The use of media to publicise fines and attract media attention to those that breach the code, maybe in many cases, more harm than the actual fines.

The new advertisement framework provides requirements for any advertisement and marketing activity in Australia. Please reach out to us if you have questions regarding the compliance of your advertisement activities in Australia.

References:

Main article source published by TGA on July 8th 2020: https://www.tga.gov.au/media-release/tga-issues-fines-nearly-18-million-alleged-illegal-activity-2019-20

Report for Review of Therapeutic Goods Advertising Framework-August 10th 2020:
https://www.tga.gov.au/sites/default/files/review-therapeutic-goods-advertising-framework.pdf

Australian Government response to the Review of the Reforms to the Therapeutic Goods Advertising Framework-August 10th 2020: https://www.tga.gov.au/australian-government-response-review-reforms-therapeutic-goods-advertising-framework

TGA issues fines of nearly $1.8 million for alleged illegal activity in 2019-20:
https://www.tga.gov.au/media-release/tga-issues-fines-nearly-18-million-alleged-illegal-activity-2019-20

We tailor our services to the requirements of your business and can help you implement plans that are best suited to your projects. 

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 28th, 2022

eCTD in Australia: key steps to start a successful submission

08:30 am CET / 4:30 pm AEST

June 28th, 2022

An Introduction to Bayesian adaptive methods in clinical trials

04:00 PM CET

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
24 Jun

Milena Shuytsova-Mircheva and Lisa Pascoe latest blog here https://www.pharmalex.com/sponsors-gear-up-for-a-smoother-process-with-ctis-but-must-first-overcome-key-hurdles/ discusses the benefit of the Clinical Trial Information System (CTIS).

💡 Interested in CTIS? Take the Phlexglobal survey to evaluate your preparation https://www.phlexglobal.com/ctis-survey

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • Our project team were very impressed with the quality of the research and the reports that you sent through. We didn’t need any convincing that your recommendations should be followed. It showed PharmaLex in a very positive light, and the Project Team are keen to work with you again.

    Leading European Specialist Pharma Company
    Head of Medical Writing and Publications
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for